130 related articles for article (PubMed ID: 22059882)
21. Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist.
Fretz H; Valdenaire A; Pothier J; Hilpert K; Gnerre C; Peter O; Leroy X; Riederer MA
J Med Chem; 2013 Jun; 56(12):4899-911. PubMed ID: 23721423
[TBL] [Abstract][Full Text] [Related]
22. The discovery of small molecule inhibitors of neutral endopeptidase. Structure-activity studies on functionalized glutaramides.
Maw GN; Stobie A; Planken S; Pryde DC; Sanderson V; Platts MY; Corless M; Stacey P; Wayman C; Van Der Graaf P; Kohl C; Coggon S; Beaumont K
Chem Biol Drug Des; 2006 Jan; 67(1):74-7. PubMed ID: 16492151
[TBL] [Abstract][Full Text] [Related]
23. Structure-based design, synthesis, and structure-activity relationship studies of novel non-nucleoside adenosine deaminase inhibitors.
Terasaka T; Kinoshita T; Kuno M; Seki N; Tanaka K; Nakanishi I
J Med Chem; 2004 Jul; 47(15):3730-43. PubMed ID: 15239652
[TBL] [Abstract][Full Text] [Related]
24. Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.
Raboisson P; Desjarlais RL; Reed R; Lattanze J; Chaikin M; Manthey CL; Tomczuk BE; Marugán JJ
Eur J Med Chem; 2007 Mar; 42(3):334-43. PubMed ID: 17184884
[TBL] [Abstract][Full Text] [Related]
25. Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).
Sturino CF; O'Neill G; Lachance N; Boyd M; Berthelette C; Labelle M; Li L; Roy B; Scheigetz J; Tsou N; Aubin Y; Bateman KP; Chauret N; Day SH; Lévesque JF; Seto C; Silva JH; Trimble LA; Carriere MC; Denis D; Greig G; Kargman S; Lamontagne S; Mathieu MC; Sawyer N; Slipetz D; Abraham WM; Jones T; McAuliffe M; Piechuta H; Nicoll-Griffith DA; Wang Z; Zamboni R; Young RN; Metters KM
J Med Chem; 2007 Feb; 50(4):794-806. PubMed ID: 17300164
[TBL] [Abstract][Full Text] [Related]
26. Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain.
Colucci J; Boyd M; Berthelette C; Chiasson JF; Wang Z; Ducharme Y; Friesen R; Wrona M; Levesque JF; Denis D; Mathieu MC; Stocco R; Therien AG; Clarke P; Rowland S; Xu D; Han Y
Bioorg Med Chem Lett; 2010 Jun; 20(12):3760-3. PubMed ID: 20471829
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological cross-reactivity between 5-lipoxygenase-activating protein, 5-lipoxygenase, and leukotriene C4 synthase.
Gupta N; Nicholson DW; Ford-Hutchinson AW
Can J Physiol Pharmacol; 1997; 75(10-11):1212-9. PubMed ID: 9431445
[TBL] [Abstract][Full Text] [Related]
28. Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor.
Hoglen NC; Chen LS; Fisher CD; Hirakawa BP; Groessl T; Contreras PC
J Pharmacol Exp Ther; 2004 May; 309(2):634-40. PubMed ID: 14742742
[TBL] [Abstract][Full Text] [Related]
29. New N-(pyridin-4-yl)-(indol-3-yl)acetamides and propanamides as antiallergic agents.
Menciu C; Duflos M; Fouchard F; Le Baut G; Emig P; Achterrath U; Szelenyi I; Nickel B; Schmidt J; Kutscher B; Günther E
J Med Chem; 1999 Feb; 42(4):638-48. PubMed ID: 10052971
[TBL] [Abstract][Full Text] [Related]
30. Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors.
Frenette R; Hutchinson JH; Léger S; Thérien M; Brideau C; Chan CC; Charleson S; Ethier D; Guay J; Jones TR; McAuliffe M; Piechuta H; Riendeau D; Tagari P; Girard Y
Bioorg Med Chem Lett; 1999 Aug; 9(16):2391-6. PubMed ID: 10476875
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic and pharmacodynamic study of a new nonsteroidal 5 alpha-reductase inhibitor, 4-[3-[3-[Bis(4-isobutylphenyl)methylamino]benzoyl]-1H-indol-1-yl]-butyr ic acid, in rats.
Katashima M; Yamamoto K; Tokuma Y; Hata T; Sawada Y; Iga T
J Pharmacol Exp Ther; 1998 Mar; 284(3):914-20. PubMed ID: 9495849
[TBL] [Abstract][Full Text] [Related]
32. (D)-2-tert-Butoxycarbonylamino-5,5-difluoro-5-phenyl-pentanoic acid: synthesis and incorporation into the growth hormone secretagogues.
Li J; Chen SY; Murphy BJ; Flynn N; Seethala R; Slusarchyk D; Yan M; Sleph P; Zhang H; Humphreys WG; Ewing WR; Robl JA; Gordon D; Tino JA
Bioorg Med Chem Lett; 2008 Jul; 18(14):4072-4. PubMed ID: 18554903
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and pharmacological evaluation of N-(3-(1H-indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide (LP-261), a potent antimitotic agent.
Shetty RS; Lee Y; Liu B; Husain A; Joseph RW; Lu Y; Nelson D; Mihelcic J; Chao W; Moffett KK; Schumacher A; Flubacher D; Stojanovic A; Bukhtiyarova M; Williams K; Lee KJ; Ochman AR; Saporito MS; Moore WR; Flynn GA; Dorsey BD; Springman EB; Fujimoto T; Kelly MJ
J Med Chem; 2011 Jan; 54(1):179-200. PubMed ID: 21126027
[TBL] [Abstract][Full Text] [Related]
34. DNA-dependent protein kinase (DNA-PK) inhibitors. Synthesis and biological activity of quinolin-4-one and pyridopyrimidin-4-one surrogates for the chromen-4-one chemotype.
Cano C; Barbeau OR; Bailey C; Cockcroft XL; Curtin NJ; Duggan H; Frigerio M; Golding BT; Hardcastle IR; Hummersone MG; Knights C; Menear KA; Newell DR; Richardson CJ; Smith GC; Spittle B; Griffin RJ
J Med Chem; 2010 Dec; 53(24):8498-507. PubMed ID: 21080722
[TBL] [Abstract][Full Text] [Related]
35. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile.
Argentieri DC; Ritchie DM; Ferro MP; Kirchner T; Wachter MP; Anderson DW; Rosenthale ME; Capetola RJ
J Pharmacol Exp Ther; 1994 Dec; 271(3):1399-408. PubMed ID: 7996452
[TBL] [Abstract][Full Text] [Related]
36. Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A(2B) adenosine receptor antagonists.
Eastwood P; Gonzalez J; Paredes S; Nueda A; Domenech T; Alberti J; Vidal B
Bioorg Med Chem Lett; 2010 Mar; 20(5):1697-700. PubMed ID: 20137946
[TBL] [Abstract][Full Text] [Related]
37. Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition.
Charleson S; Prasit P; Léger S; Gillard JW; Vickers PJ; Mancini JA; Charleson P; Guay J; Ford-Hutchinson AW; Evans JF
Mol Pharmacol; 1992 May; 41(5):873-9. PubMed ID: 1588922
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile (WAY-255348).
Fensome A; Adams WR; Adams AL; Berrodin TJ; Cohen J; Huselton C; Illenberger A; Kern JC; Hudak VA; Marella MA; Melenski EG; McComas CC; Mugford CA; Slayden OD; Yudt M; Zhang Z; Zhang P; Zhu Y; Winneker RC; Wrobel JE
J Med Chem; 2008 Mar; 51(6):1861-73. PubMed ID: 18318463
[TBL] [Abstract][Full Text] [Related]
39. Substituted 2,2-bisaryl-bicycloheptanes as novel and potent inhibitors of 5-lipoxygenase activating protein.
Macdonald D; Brideau C; Chan CC; Falgueyret JP; Frenette R; Guay J; Hutchinson JH; Perrier H; Prasit P; Riendeau D; Tagari P; Thérien M; Young RN; Girard Y
Bioorg Med Chem Lett; 2008 Mar; 18(6):2023-7. PubMed ID: 18276139
[TBL] [Abstract][Full Text] [Related]
40. Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P₁ agonists.
Buzard D; Han S; Thoresen L; Moody J; Lopez L; Kawasaki A; Schrader T; Sage C; Gao Y; Edwards J; Barden J; Thatte J; Fu L; Solomon M; Liu L; Al-Shamma H; Gatlin J; Le M; Xing C; Espinola S; Jones RM
Bioorg Med Chem Lett; 2011 Oct; 21(19):6013-8. PubMed ID: 21852130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
